文献速递临床试验与 GCP基础与转化研究

谷氨酸输注对高危患者冠状动脉旁路移植术后NT-proBNP的影响(GLUTAMICS II):一项随机对照试验

Effect of glutamate infusion on NT-proBNP after coronary artery bypass grafting in high-risk patients (GLUTAMICS II): A randomized controlled trial.
PubMed 文献 · PLoS Med · 2022-05-09

在瑞典4个心脏外科中心开展的前瞻性、随机、双盲试验,纳入303例接受CABG±瓣膜手术且LVEF≤0.30或EuroSCORE II≥3.0的患者,比较谷氨酸与生理盐水输注对术后第3天NT-proBNP升幅的影响。结果显示谷氨酸组与对照组主要终点无显著差异(5390±5396 ng/L vs 6452±5215 ng/L,p=0.086),但在无糖尿病患者中谷氨酸组主要终点和急性肾损伤发生率均降低。

要点

  • 谷氨酸输注未显著降低CABG术后NT-proBNP升幅(p=0.086)。
  • 谷氨酸与糖尿病存在显著交互作用(p=0.03)。
  • 无糖尿病患者中谷氨酸组NT-proBNP升幅和急性肾损伤发生率降低。

核心结论

  • 谷氨酸输注未显著降低CABG术后NT-proBNP升幅。
  • 糖尿病患者与非糖尿病患者结果不一致,与既往观察一致,提示以谷氨酸促进缺血后心肌恢复的概念值得进一步评估。

研究设计与样本

  • 前瞻性、随机、双盲研究,2015年11月15日至2020年9月30日入组,随访30天,在瑞典4个学术心脏外科中心开展。
  • 患者接受CABG±瓣膜手术,且左心室射血分数≤0.30或EuroSCORE II≥3.0。
  • 共研究303例患者(年龄74±7岁;女性26%,糖尿病47%),谷氨酸组148例,对照组155例。
  • 干预为静脉输注0.125 M L-谷氨酸或生理盐水,速度1.65 mL/kg/h,于松开主动脉阻断钳前10至20分钟开始,之后继续输注150分钟。
  • 主要终点为术前与术后第3天NT-proBNP水平的差值,分析为意向性治疗。

主要发现

  • 主要终点在谷氨酸组与对照组间无显著差异(5390±5396 ng/L vs 6452±5215 ng/L;p=0.086)。
  • 谷氨酸组30天内死亡1例,对照组6例(0.7% vs 3.9%;p=0.12)。
  • 未观察到与谷氨酸相关的不良事件。
  • 谷氨酸与糖尿病存在显著交互作用(p=0.03)。
  • 无糖尿病患者中,谷氨酸组主要终点低于对照组(平均4503±4846 ng/L vs 6824±5671 ng/L;p=0.007),急性肾损伤发生率低于对照组(11% vs 29%;p=0.005);校正基线差异后这些关联仍显著。

局限性

  • 研究依赖心力衰竭的替代标志物。
  • 与样本量估算所用队列相比,糖尿病患者比例几乎翻倍。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Animal and human data suggest that glutamate can enhance recovery of myocardial metabolism and function after ischemia. N-terminal pro-brain natriuretic peptide (NT-proBNP) reflects myocardial dysfunction after coronary artery bypass surgery (CABG). We investigated whether glutamate infusion can reduce rises of NT-proBNP in moderate- to high-risk patients after CABG. METHODS AND FINDINGS: A prospective, randomized, double-blind study enrolled patients from November 15, 2015 to September 30, 2020, with a 30-day follow-up at 4 academic cardiac surgery centers in Sweden. Patients underwent CABG ± valve procedure and had left ventricular ejection fraction ≤0.30 or EuroSCORE II ≥3.0. Intravenous infusion of 0.125 M L-glutamic acid or saline at 1.65 mL/kg/h started 10 to 20 minutes before releasing the aortic cross-clamp, then continued for another 150 minutes. Patients, staff, and investigators were blinded to the treatment. The primary endpoint was the difference between preoperative and day-3 postoperative NT-proBNP levels. Analysis was intention to treat. We studied 303 patients (age 74 ± 7 years; females 26%, diabetes 47%), 148 receiving glutamate group and 155 controls. There was no significant difference in the primary endpoint associated with glutamate administration (5,390 ± 5,396 ng/L versus 6,452 ± 5,215 ng/L; p = 0.086). One patient died ≤30 days in the glutamate group compared to 6 controls (0.7% versus 3.9%; p = 0.12). No adverse events linked to glutamate were observed. A significant interaction between glutamate and diabetes was found (p = 0.03). Among patients without diabetes the primary endpoint (mean 4,503 ± 4,846 ng/L versus 6,824 ± 5,671 ng/L; p = 0.007), and the incidence of acute kidney injury (11% versus 29%; p = 0.005) was reduced in the glutamate group. These associations remained significant after adjusting for differences in baseline data. The main limitations of the study are: (i) it relies on a surrogate marker for heart failure; and (ii) the proportion of patients with diabetes had almost doubled compared to the cohort used for the sample size estimation. CONCLUSIONS: Infusion of glutamate did not significantly reduce postoperative rises of NT-proBNP. Diverging results in patients with and without diabetes agree with previous observations and suggest that the concept of enhancing postischemic myocardial recovery with glutamate merits further evaluation. TRIAL REGISTRATION: ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02592824. European Union Drug Regulating Authorities Clinical Trials Database (Eudra CT number 2011-006241-15).

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. Holm J, Ferrari G, Holmgren A, et al. Effect of glutamate infusion on NT-proBNP after coronary artery bypass grafting in high-risk patients (GLUTAMICS II): A randomized controlled trial. PLoS Med. 2022. PMID: 35533197. doi:10.1371/journal.pmed.1003997

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。